August 20th, 2012
Questcor Pharmaceuticals, Inc. (QCOR)
Prev close $50.52
Open $50.51
Close 26.35
24.17(47.84%)
after hours
(as of 8:30 est)
$27.10
Do
not panic. Any move we do will lock in a loss. I am going to HOLD
because the fundamentals are still strong and Aetna only represents 5% of the companies sales.
What happened you ask?
He is a short explaination
http://www.thestreet.com/story/11710719/1/questcor-pharmaceuticals-inc-qcor-todays-featured-drugs-laggard.html?puc=yahoo&cm_ven=YAHOO
And I will re
print a more detailed article below.
Rule#1 Don’t lose Money.
The Rowboat System has been through worse than this, and we have recovered eventually; almost
every time.
There are only 3 ways we can react.
1.
Buy back the put @ over $9.00 locking in a $830
. loss per contract.
2.
Short the stock @ $27.00, locking in a $800 loss per contract.
3.
Let it get put to us, and sell covered calls on it.
Most recently FMCN dropped from $20.00 To under $10.00 per share and we will probably be called
away at over $27.0
0.
The Old timers have seen this happen before, so this is for the new subscribers, who might be a little
wobbly.
This stock should be trading in the $40

50 dollar range, so just be patient. The fundamentals are
strong. Below is a reprint of a more d
etailed article:
DJ Questcor Shares Plunge on Worries About Aetna Coverage of Acthar
By Anna Prior
Questcor Pharmaceuticals Inc. (QCOR) shares plunged Wednesday after insurer Aetna Inc. (AET)
limited reimbursement of the pharmaceutical company’
s only drug, Acthar, for treatment of infantile
spasms.
Shares recently dropped 40% to $30.05 on heavy volume and earlier hit a 52

week low of $22.26 as
Aetna called the drug medically unnecessary to treat certain other conditions.
Noted short

seller Cit
ron Research highlighted a policy bulletin on Aetna’s website from Friday that
called Acthar medically necessary for West syndrome, a relatively rare neurological disorder that
causes infantile spasms, but described its use for several other conditions as
medically unnecessary, or
investigational and experimental.
Representatives from Questcor weren’t immediately available for comment.
An Aetna spokeswoman told Dow Jones the decision was based on the lack of clinical evidence that
the drug is more effecti
ve than steroids, adding its position is based on an analysis of the available data
and is supported by public statements from the chief medical officer of the National Multiple Sclerosis
Society. It will review the policy based on any new clinical data on
Oct. 13.
In 2010, the U.S. Food and Drug Administration updated its approval of Acthar to cover 19 different
indications, narrowing the company’s immediate focus for growth to patients suffering from kidney

related disorders.
Questcor originally sold th
e drug to address infantile spasms, but now markets the compound for
multiple sclerosis flare

ups and is funding an exploratory study for patients whose kidney problems are
caused by diabetes, opening the company up to a potentially massive market. Treatme
nts for kidney

related disorders seem to represent the next frontier for the drug.
Potential future uses include treatment for proteinuria among diabetics, lupus and rheumatic diseases.
Write to Anna Prior at anna.prior@dowjones.com
Subscribe to WSJ: htt
p://online.wsj.com?mod=djnwires
Until next time.
Brad lee
The Options Oracle.
Brad Lee AKA “The Options Oracle” and “The Money Medic” is an individual investor who does not manage
money for any financial institution. You are purchasing the lis
t of stocks that he uses to select options contracts
he feels will return him the highest, safest profits. Brad is not a broker, or financial adviser. He is a remarkable
investor who has developed a successful strategy for himself, and is willing to share
some of his magic with you.
We urge you to paper trade these picks and learn how to develop a strategy that is appropriate for you.Thank
You.
Disclaimer
Trading or investment in stocks, futures & options, and commodity are subject to potential market
risks. You can use our materials or
recommendations for educational purposes, this is not intended as Trading or Investment advice.
We are not financial advisers. We cannot
provide any advice as to whether or not options or our trading ideas are suitable
investments for your particular financial situation. We are in
the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation
with a qualified registered financial adviser/plann
er.
This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is
confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please
also disregard the
contents of the email, delete it and destroy any copies immediately.
You may download and retain on your disk or in hard

copy form a single copy of material published on this site only for your
personal, non

commercial use, provided th
at you do not remove any copyright or other proprietary notices. You may not otherwise
copy, distribute, display, download, modify, repost, transmit or use all or part of any material without prior written permission.